Related references
Note: Only part of the references are listed.Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver Ottmann et al.
BLOOD (2007)
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial
Hagop Kantarjian et al.
BLOOD (2007)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot et al.
BLOOD (2007)
The CXCR4 chemokine receptor in acute and chronic leukaemia:: a marrow homing receptor and potential therapeutic target
Jan A. Burger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Jorge Cortes et al.
BLOOD (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy
Ahmed Abdelhalim et al.
LEUKEMIA & LYMPHOMA (2007)
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
Daniela S. Krause et al.
NATURE MEDICINE (2006)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia
A Castor et al.
NATURE MEDICINE (2005)
Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate
M Matsuda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with Imatinib (STI-571)
JF Leis et al.
LEUKEMIA & LYMPHOMA (2004)
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy
S Bujassoum et al.
LEUKEMIA & LYMPHOMA (2004)
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Y Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib
S Soverini et al.
CLINICAL CHEMISTRY (2004)
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid
M Bornhauser et al.
ANNALS OF HEMATOLOGY (2004)
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells
A Ptasznik et al.
NATURE MEDICINE (2004)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia
NC Wolff et al.
BLOOD (2003)
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux
HQ Dai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid
N Takayama et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo
K Porkka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
Central nervous system involvement in adult acute lymphocytic leukemia
J Cortes
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2001)
Share Paper
